Response to comment on: "Efficacy and safety of tebentafusp in patients with metastatic uveal melanoma: A systematic review and meta-analysis".
作者信息
Chen Danyao, Sun Yuming, Dian Yating, Deng Guangtong
机构信息
Department of Dermatology, Xiangya Hospital, Central South University, Changsha, China.
National Engineering Research Center of Personalized Diagnostic and Therapeutic Technology, Changsha, China.
出版信息
Hum Vaccin Immunother. 2024 Dec 31;20(1):2398874. doi: 10.1080/21645515.2024.2398874. Epub 2024 Oct 21.
Abstract
摘要
相似文献
1
Response to comment on: "Efficacy and safety of tebentafusp in patients with metastatic uveal melanoma: A systematic review and meta-analysis".对关于“替贝福司对转移性葡萄膜黑色素瘤患者的疗效和安全性：一项系统评价和荟萃分析”评论的回应
Hum Vaccin Immunother. 2024 Dec 31;20(1):2398874. doi: 10.1080/21645515.2024.2398874. Epub 2024 Oct 21.
2
Efficacy and safety of tebentafusp in patients with metastatic uveal melanoma: A systematic review and meta-analysis.特普替尼治疗转移性葡萄膜黑色素瘤患者的疗效和安全性：系统评价和荟萃分析。
Hum Vaccin Immunother. 2024 Dec 31;20(1):2374647. doi: 10.1080/21645515.2024.2374647. Epub 2024 Jul 14.
3
Tebentafusp in advanced uveal melanoma: proof of principle for the efficacy of T-cell receptor therapeutics and bispecifics in solid tumors.替本福司他在晚期葡萄膜黑色素瘤中的应用：证明了 T 细胞受体疗法和双特异性药物在实体肿瘤中的疗效。
Expert Opin Biol Ther. 2022 Aug;22(8):997-1004. doi: 10.1080/14712598.2022.2031970. Epub 2022 Feb 2.
4
Tebentafusp for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma.特必津治疗 HLA-A*02:01 阳性不可切除或转移性葡萄膜黑素瘤的成年患者。
Expert Rev Anticancer Ther. 2022 Oct;22(10):1017-1027. doi: 10.1080/14737140.2022.2124971. Epub 2022 Sep 19.
5
Comment on: "Efficacy and safety of tebentafusp in patients with metastatic uveal melanoma: A systematic review and meta-analysis".评论：“替贝福司对转移性葡萄膜黑色素瘤患者的疗效和安全性：一项系统评价和荟萃分析”
Hum Vaccin Immunother. 2024 Dec 31;20(1):2398870. doi: 10.1080/21645515.2024.2398870. Epub 2024 Oct 21.
6
T Cell-Engaging Bispecific Antibodies Targeting gp100 and PRAME: Expanding Application from Uveal Melanoma to Cutaneous Melanoma.靶向gp100和PRAME的T细胞接合双特异性抗体：从葡萄膜黑色素瘤到皮肤黑色素瘤的应用拓展
Pharmaceutics. 2024 Aug 6;16(8):1046. doi: 10.3390/pharmaceutics16081046.
7
Tebentafusp: First Approval.特泊替尼：首次获批。
Drugs. 2022 Apr;82(6):703-710. doi: 10.1007/s40265-022-01704-4.
8
Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma.转移性葡萄膜黑色素瘤患者使用替本福司他治疗的 3 年总生存率。
N Engl J Med. 2023 Dec 14;389(24):2256-2266. doi: 10.1056/NEJMoa2304753. Epub 2023 Oct 21.
9
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma.特普替尼治疗转移性葡萄膜黑色素瘤的总生存获益。
N Engl J Med. 2021 Sep 23;385(13):1196-1206. doi: 10.1056/NEJMoa2103485.
10
Tebentafusp for the treatment of metastatic uveal melanoma.特贝妥珠单抗治疗转移性葡萄膜黑色素瘤。
Future Oncol. 2022 Apr;18(11):1303-1311. doi: 10.2217/fon-2021-1260. Epub 2022 Feb 17.
本文引用的文献
1
Comment on: "Efficacy and safety of tebentafusp in patients with metastatic uveal melanoma: A systematic review and meta-analysis".评论：“替贝福司对转移性葡萄膜黑色素瘤患者的疗效和安全性：一项系统评价和荟萃分析”
Hum Vaccin Immunother. 2024 Dec 31;20(1):2398870. doi: 10.1080/21645515.2024.2398870. Epub 2024 Oct 21.
2
Efficacy and safety of tebentafusp in patients with metastatic uveal melanoma: A systematic review and meta-analysis.特普替尼治疗转移性葡萄膜黑色素瘤患者的疗效和安全性：系统评价和荟萃分析。
Hum Vaccin Immunother. 2024 Dec 31;20(1):2374647. doi: 10.1080/21645515.2024.2374647. Epub 2024 Jul 14.
3
A new improved graphical and quantitative method for detecting bias in meta-analysis.一种新的改进的图形和定量方法，用于检测荟萃分析中的偏倚。
Int J Evid Based Healthc. 2018 Dec;16(4):195-203. doi: 10.1097/XEB.0000000000000141.
4
Plea for routinely presenting prediction intervals in meta-analysis.呼吁在荟萃分析中常规呈现预测区间。
BMJ Open. 2016 Jul 12;6(7):e010247. doi: 10.1136/bmjopen-2015-010247.
5
GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology.GRADE 指南：《临床流行病学杂志》的一系列新文章。
J Clin Epidemiol. 2011 Apr;64(4):380-2. doi: 10.1016/j.jclinepi.2010.09.011. Epub 2010 Dec 24.
6
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations.GRADE：关于证据质量评级和推荐强度的新共识。
BMJ. 2008 Apr 26;336(7650):924-6. doi: 10.1136/bmj.39489.470347.AD.
Zotero 插件